{"id":915735,"date":"2025-12-03T11:23:57","date_gmt":"2025-12-03T16:23:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/"},"modified":"2025-12-03T11:23:57","modified_gmt":"2025-12-03T16:23:57","slug":"kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/","title":{"rendered":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia"},"content":{"rendered":"<h2>\nEvent Scheduled for December 8, 2025 at 12:30 PM ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>SAN DIEGO, Dec.  03, 2025  (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET \/ 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI<sup>\u00ae<\/sup>) with venetoclax and azacitidine in newly diagnosed and relapsed\/refractory acute myeloid leukemia <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z2MkXGAEU7xxQ--_uMeI0OyM5reSOZV-mp8WN2lY0qdvxgx63TQmLcRMTJ3rKs-Vlekv0c8tpwuevkbOjtLCf0iIXF2tppb-IXm70b_64wmyxqED0p53deKq4X1sHP37xjTP5MFT1gcpQGBsBWr11yBasbTzg7e4s6JpXaFrfi-7AXEpeJcTqJzWN7tTJww9aIqR50QW9m5uILygPxIzmvhpSpsdwgeBdNzjuRXmE5pHi9bRA_hXb_hsa6wQalJ1\" rel=\"nofollow\" target=\"_blank\">scheduled for presentation<\/a> at the 67th American Society of Hematology (ASH) Annual Meeting.<\/p>\n<p>The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UtsJXZlU8nG_0949sxIAI7KDZs0rcWzXcHhl2vwWoC2Lnm39mvz1i2vaQSfO1vPgpaNT3PMywkkrAx-mqqwB-aOZTnmgkDyBtHmErgj890Q=\" rel=\"nofollow\" target=\"_blank\">www.kuraoncology.com<\/a> under the Investors tab in the Events and Presentations section.<\/p>\n<p>\n        <strong>About\u00a0Kura Oncology <\/strong><br \/>\n        <br \/>Kura Oncology\u00a0is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura\u2019s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI\u2122, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory\u00a0<em>NPM1<\/em>-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RbnjYpI6-lXQOm_wn6pgCEklFplF5vMjRQlzRU_Lf0LhZ7FmgAvnSKgDpT03nkFoqkcDEtYGbWCJr7Z3GMHDZb5NUUssVrFCvXenhvSuJlA=\" rel=\"nofollow\" target=\"_blank\">https:\/\/kuraoncology.com\/<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j1LT-4Vs0aehz6k8hSC7fu0VGJ6-o_Ow8A9NofNUvamLH5qPJNbKVpV_9hhKddbdIt783H-kKxehLuLJR2z7fg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rB3zAs5-rC9moAJ8hSLUPH-zNpG-B4XJ8a0lTExEtFb4a8krrro5yaSzNUgjiHJb6ZdNBkI4wBslwHuobvA9M8hFIBXp3WPMJLj0efU2xJsTWB2pXOwkuNjKO9eqoyMA\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Kura Contact<\/strong>\n      <\/p>\n<p>Investors and Media:<br \/>Greg Mann<br \/>858-987-4046<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lzdGBpEHxLE78jWZkSSPg_Y9k8lbX2CarocDn7x_Xsan7G-YmSsj9e2mIDw2K696cnpxySFtamh5M82Fq6aVhZCvpg9zD_kdEBIeZZLi6Po=\" rel=\"nofollow\" target=\"_blank\">gmann@kuraoncology.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjBmOTY3ZWItMzdjOS00YjFjLThhMzUtZDg2N2NhMjU4OTkzLTEwMjg3NjgtMjAyNS0xMi0wMy1lbg==\/tiny\/Kura-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Event Scheduled for December 8, 2025 at 12:30 PM ET SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET \/ 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI\u00ae) with venetoclax and azacitidine in newly diagnosed and relapsed\/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting. The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915735","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Event Scheduled for December 8, 2025 at 12:30 PM ET SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET \/ 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI\u00ae) with venetoclax and azacitidine in newly diagnosed and relapsed\/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting. The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be &hellip; Continue reading &quot;Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T16:23:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\\\/Refractory Acute Myeloid Leukemia\",\"datePublished\":\"2025-12-03T16:23:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/\",\"name\":\"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\\\/Refractory Acute Myeloid Leukemia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\",\"datePublished\":\"2025-12-03T16:23:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\\\/Refractory Acute Myeloid Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/","og_locale":"en_US","og_type":"article","og_title":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia - Market Newsdesk","og_description":"Event Scheduled for December 8, 2025 at 12:30 PM ET SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET \/ 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI\u00ae) with venetoclax and azacitidine in newly diagnosed and relapsed\/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting. The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be &hellip; Continue reading \"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T16:23:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia","datePublished":"2025-12-03T16:23:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/","name":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=","datePublished":"2025-12-03T16:23:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTg4MyM3MzAzNDU4IzIwMTcxOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-host-virtual-investor-event-to-discuss-data-presented-at-ash-2025-on-triplet-combination-of-ziftomenib-komzifti-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsed\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI\u00ae) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed\/Refractory Acute Myeloid Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915735"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}